The FDA’s big Gamble on the new Alzheimer’s Drug

The FDA’s big Gamble on the new Alzheimer’s Drug

By C. Michael White, The Conversation The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated approval pathway. This decision ignored the recommendation of the FDA’s external advisory panel to reject the drug. The FDA grants accelerated approvals for drugs to […]